Matches in DBpedia 2015-04 for { <http://dbpedia.org/resource/Infliximab> ?p ?o }
Showing triples 1 to 83 of
83
with 100 triples per page.
- Infliximab abstract "Infliximab (INN; trade name Remicade) is a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-α) used to treat autoimmune diseases.Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab won its initial approval by the FDA for the treatment of Crohn's disease in August 1998.Infliximab works by binding to TNF-α. TNF-α is a chemical messenger (cytokine) and a key part of the autoimmune reaction. In rheumatoid arthritis, infliximab seems to work by preventing TNF-α from binding to its receptor in the cell.Infliximab is an artificial antibody. It was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. The antibodies in the titre are monospecific antibodies i.e. they are same in structure and their affinity to the target, it is called a monoclonal antibody. Furthermore, as a combination of mouse and human antibody amino acid sequences, it is called a chimeric monoclonal antibody.Infliximab was developed by Junming Le and Jan Vilcek at New York University School of Medicine and developed by Centocor, (now Janssen Biotech, Inc.)Remicade is marketed by Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.) in the USA, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-Plough (now part of Merck & Co) elsewhere. In 2013, two biosimilars were submitted for approval in Europe, by Hospira and Celltrion Healthcare. In India, Epirus Biopharmaceuticals has obtained approval to produce infliximab under the brand name "Infimab" (trail name BOW015).In the United States, Infliximab can cost $19,000 to $22,000 a year per patient wholesale, according to Centocor.Other monoclonal antibodies targeting TNF-α are golimumab (Simponi), adalimumab (Humira), and certolizumab pegol (Cimzia). Etanercept also binds and inhibits the action of TNF-α, but is not a monoclonal antibody (it is instead a fusion of TNF-receptor and an antibody constant region).Infliximab is administered by intravenous infusion, typically at six- to eight-week intervals, at a clinic or hospital. It cannot be administered orally because the digestive system would destroy the drug.".
- Infliximab atcPrefix "L04".
- Infliximab atcSuffix "AB02".
- Infliximab bioavailability "92.0".
- Infliximab casNumber "170277-31-3".
- Infliximab drugbank "DB00065".
- Infliximab fdaUniiCode "B72HH48FLU".
- Infliximab thumbnail Infliximab_structure2.jpg?width=300.
- Infliximab wikiPageExternalLink remicade.
- Infliximab wikiPageExternalLink antitnfa_treatment_in_rheumatoid_arthritis.aspx.
- Infliximab wikiPageExternalLink www.remicade.com.
- Infliximab wikiPageExternalLink hcp_pi.html.
- Infliximab wikiPageID "324466".
- Infliximab wikiPageRevisionID "642884135".
- Infliximab atcPrefix "L04".
- Infliximab atcSuffix "AB02".
- Infliximab bioavailability "92.0".
- Infliximab c "6428".
- Infliximab casNumber "170277".
- Infliximab chembl "1201581".
- Infliximab chemspiderid "NA".
- Infliximab drugbank "DB00065".
- Infliximab eliminationHalfLife "820800.0".
- Infliximab h "9912".
- Infliximab hasPhotoCollection Infliximab.
- Infliximab kegg "D02598".
- Infliximab legalAu "S4".
- Infliximab legalCa "Rx-only".
- Infliximab legalUk "POM".
- Infliximab legalUs "Rx-only".
- Infliximab mabType "mab".
- Infliximab metabolism "reticuloendothelial system".
- Infliximab molecularWeight "144190.3".
- Infliximab n "1694".
- Infliximab o "1987".
- Infliximab pregnancyAu "C".
- Infliximab pregnancyUs "B".
- Infliximab routesOfAdministration "IV".
- Infliximab s "46".
- Infliximab source "xi/o".
- Infliximab target Tumor_necrosis_factors.
- Infliximab tradename "Remicade".
- Infliximab type "mab".
- Infliximab unii "B72HH48FLU".
- Infliximab verifiedfields "changed".
- Infliximab verifiedrevid "458271995".
- Infliximab subject Category:Engineered_proteins.
- Infliximab subject Category:Immunosuppressants.
- Infliximab subject Category:Janssen_Biotech.
- Infliximab subject Category:Monoclonal_antibodies.
- Infliximab subject Category:Schering-Plough.
- Infliximab subject Category:TNF_inhibitors.
- Infliximab type Drug.
- Infliximab type DrugProduct.
- Infliximab type Thing.
- Infliximab type Q8386.
- Infliximab comment "Infliximab (INN; trade name Remicade) is a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-α) used to treat autoimmune diseases.Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab won its initial approval by the FDA for the treatment of Crohn's disease in August 1998.Infliximab works by binding to TNF-α.".
- Infliximab label "Infliksymab".
- Infliximab label "Infliximab".
- Infliximab label "Infliximab".
- Infliximab label "Infliximab".
- Infliximab label "Infliximab".
- Infliximab label "Infliximab".
- Infliximab label "Infliximab".
- Infliximab label "Infliximabe".
- Infliximab label "Инфликсимаб".
- Infliximab label "インフリキシマブ".
- Infliximab sameAs Infliximab.
- Infliximab sameAs Infliximab.
- Infliximab sameAs Infliximab.
- Infliximab sameAs Infliximab.
- Infliximab sameAs インフリキシマブ.
- Infliximab sameAs Infliximab.
- Infliximab sameAs Infliksymab.
- Infliximab sameAs Infliximabe.
- Infliximab sameAs m.01vzrk.
- Infliximab sameAs Q415264.
- Infliximab sameAs Q415264.
- Infliximab sameAs infliximab.
- Infliximab sameAs DB00065.
- Infliximab wasDerivedFrom Infliximab?oldid=642884135.
- Infliximab depiction Infliximab_structure2.jpg.
- Infliximab isPrimaryTopicOf Infliximab.